SlideShare una empresa de Scribd logo
1 de 50
Descargar para leer sin conexión
The role of the gynecologist in
screening & prevention of
Osteoporosis
Aboubakr Elnashar
Benha University Hospital
ABOUBAKR ELNASHAR
Outline
•Introduction
•Screening
•Prevention
•Role of gynecologist
•Conclusion
ABOUBAKR ELNASHAR
Introduction
ABOUBAKR ELNASHAR
Women health Clinic
•Screening for breast cancer
•Screening for cervical cancer
•Pre conceptional counseling
•Contraception
•Sexual dysfunction
•Menopausal
•Screening & prevention of osteoporosisABOUBAKR ELNASHAR
•Consequences of Hip Fractures
5–20%: mortality within 1 y
20%: severely impaired mobility
50%: do not regain previous mobility
• In women >50y, the lifetime risk of
(NICE,2008)
Vertebral fracture is 1/3
Hip fracture is 1/5
ABOUBAKR ELNASHAR
Osteoporosis
Silent disease {by the time any symptoms (pain &
fractures) became apparent, the disease is already far
advanced}.
The nightmares of post-menopause
Progressive, systemic disorder characterized by:
•Low bone mass
•Micro-architectural deterioration of bone tissue
•Increase in bone fragility & susceptibility to fracture
(NICE, 2008)
ABOUBAKR ELNASHAR
Normal bone Osteoporosis
Microarchitectural
deterioration
Low bone density
ABOUBAKR ELNASHAR
Sites:
Any
Common
•Lumbar & thoracic spine
•Proximal femur.
•Distal radius
ABOUBAKR ELNASHAR
Bone mass
•35% of cortical & 50% of cancellous bone mass are
lost over a lifetime
•The peak bone mass attained is a major
determinant of subsequent bone mass& fracture
risk in later life (Bonjour et al,1997).
ABOUBAKR ELNASHAR
•Determinants of peak bone mass
Genetic factors:
At least half of bone strength is attributable to genetic factors;
Genetic risk factors: age, family history, female sex, low wt, small
frame, and white or Asian race.
Gonadal status
Nutritional status
Physical activity
Modifiable factors may contribute almost equally
ABOUBAKR ELNASHAR
Screening
ABOUBAKR ELNASHAR
The US Preventive Services Task Force
American Association of Clinical Endocrinologists,
The North American Menopause Society,
The American College of Obstetricians and Gynecologists,
•Indications
ABOUBAKR ELNASHAR
ABOUBAKR ELNASHAR
ABOUBAKR ELNASHAR
ABOUBAKR ELNASHAR
Major
• Age ≥ 65 yr
• Vertebral compression fracture
• Fragility fracture after age 40 yr
• Family history of osteoporotic
fracture
• Systemic glucocorticoid therapy ≥ 3
mo
• Malabsorption syndrome
• Primary hyperparathyroidism
• Propensity to fall
• Appearance of osteopenia on
radiograph
• Hypogonadism
•Early menopause (< 45 yr)
Minor
• Rheumatoid arthritis
• History of clinical hyperthyroidism
• Long-term anticonvulsant therapy
• Weight loss > 10% of body wt at
age 25 y
• Weight < 57 kg
• Smoking
• Excess alcohol intake
• Excess caffeine intake
• Low dietary calcium intake
• Long-term heparin therapy
V. 1 major or 2 minor clinical factors
(SOGC Clinical Practice Guideline, 2009)
ABOUBAKR ELNASHAR
The FRAX® tool has been developed by WHO to evaluate
fracture risk of patients. It is based on individual patient
models that integrate the risks associated with clinical risk
factors as well as bone mineral density (BMD) at the femoral
neck.
The FRAX® models have been developed from studying
population-based cohorts from Europe, North America, Asia
and Australia. In their most sophisticated form, the FRAX®
tool is computer-driven and is available on this site. Several
simplified paper versions, based on the number of risk factors
are also available, and can be downloaded for office use.
The FRAX® algorithms give the 10-year probability of
fracture. The output is a 10-year probability of hip fracture
and the 10-year probability of a major osteoporotic fracture
(clinical spine, forearm, hip or shoulder fracture).
ABOUBAKR ELNASHAR
Age
Sex
Weight
Height
Previous fracture
Parent fractured hip
Current smoking
Glucocorticoids
Rheumatoid arthritis
Secondary osteoporosis
Alcohol 3 or more units/day
Bone mineral density
(BMD)
ABOUBAKR ELNASHAR
Methods
I. DEXA (Dual Energy X ray Absorbometry)
The best predictor of hip fracture and an equivalent predictor of other fractures.
The total hip, femoral neck, and posterior-anterior lumbar spine should be measured, using the
lowest of the three BMD scores.
The technical standard (ACOG, 2004)
•Measures important sites of osteoporotic fractures.
•High precision& accuracy.
•Relatively inexpensive
•Modest radiation exposure .
ABOUBAKR ELNASHAR
DEXA: 2 x-ray beams of different energy levels
ABOUBAKR ELNASHAR
DEXA
1
ABOUBAKR ELNASHAR
Interpreting DEXA Results
T scores (comparison with the young adult mean):
relates to absolute fracture risk
Z scores (comparison with reference values of the
same age): related to the individual’s relative risk
for their age.
ABOUBAKR ELNASHAR
•T score ≥ -1
•T score -1 to -2.5
•T score < -2.5
Normal
Osteopenia
Osteoporosis
WHO Classification of BMD
using DEXA
•T score < -2.5
+ H. of fractureSevere Osteoporosis
T score represents the number of SD a patient is above or below
the mean BMD of a young adult. ABOUBAKR ELNASHAR
Australian Family Physician, 2004
ABOUBAKR ELNASHAR
II. Tests other than DEXA (peripheral bone
densitometry devices
(ACOG guideline, 2004)
1. Quantitative US (QUS) .
2. Single-energy x-ray absorptiometry.
3. Peripheral DEXA
4. Peripheral quantitative computed tomography
less expensive
low radiation exposure
low precision& accuracy.
Measure peripheral bone only.
Cannot replace DEXA scans .
ABOUBAKR ELNASHAR
Q US
ABOUBAKR ELNASHAR
III. Biochemical markers.
Reflect bone turnover
Have potential use in diagnosing&
monitoring therapy of osteoporosis.
Not recommended at this time.
ABOUBAKR ELNASHAR
Prevention
ABOUBAKR ELNASHAR
• Types of prevention of osteoporosis.
1. Primary:
Aims at reaching at adolescent age a peak bone
mass as high as possible.
Should begin in childhood& continue throughout the
life span to maximize bone mass.
E.g. sufficient calcium intake, omit risk factors
2. Secondary:
Aims at reducing bone loss peri & postmenopausal
E.g. estrogens/gestagens, bisphosphonates
&SERMs.
3. Tertiary:
With manifest osteoporosis aims at preventing
fractures.
ABOUBAKR ELNASHAR
Strategies for prevention of osteoporosis:
1. High risk strategy:
To identify women at risk & offer intervention
2. Global strategy:
Population based, where the aim is to modify the
risk factors in the general community
ABOUBAKR ELNASHAR
5 steps for maximizing peak bone mass
(National osteoporosis foundation)
Most important for women who haven't reached their
maximum peak bone mass, which usually occurs
around the age of 30.
Step 1: Daily recommended amounts of ca & vitamin
D
Step 2: Regular wt-bearing exercises
Step 3: Avoid smoking& excessive alcohol intake
Step 4: Risk factor assessment of developing
osteoporosis.
To institute strategies to maximize peak bone mass
and minimize loss before it is too late to prevent the
disease.
Step 5: When indicated, BMD test to see if
medication is needed ABOUBAKR ELNASHAR
5 steps to minimizing bone loss especially after
menopause
(National osteoporosis foundation)
Step 1: Balanced diet
Regular exercise program
Adequate intake of calcium in diet,
Regular sunlight exposure
Step 2: Stop smoking and reduce alcohol consumption
Step 3: Risk factor assessment & screening test
Step 4: If required, medication for osteoporosis
prevention
Step 5: Avoid certain medications
ABOUBAKR ELNASHAR
ABOUBAKR ELNASHAR
I. Improvement of nutritional intake
1. Ca
Adequate consumption of calcium is essential for bone health.
Calcium balance also can be adversely affected by dietary habits, including high intake of protein, phosphorus,
and sodium, although these effects appear to be less important when dietary calcium is sufficient.
The recommended calcium intake for postmenopausal women (1200–1500
mg/day) can be met with food sources, but supplements should be
added if needed.
Most postmenopausal women in the USA consume only about 600 mg/d.
High-calcium foods include milk (290–300 mg/cup), sardines in oil, with bones (370 mg/3 oz), yogurt (300–500 mg depending on container size),
cheese (165–270 mg/slice), canned salmon, with bones (170–210 mg/3 oz), broccoli (160–180 mg/cup), and tofu (144–155 mg/4 oz).
ABOUBAKR ELNASHAR
2. Vitamin D
Essential for intestinal absorption of calcium.
The recommended intake for women is
400 IU/d for ages 51 to 70,
600 IU/d over age 70, and
800 IU/day for all high-risk women
(homebound, institutionalized, on chronic glucocorticoids, or who live in northern latitudes and
therefore have limited exposure to sunlight)
Sources of vitamin D include sunlight, vitamin D–fortified foods, fish oils, and supplements.
Multivitamins typically contain 400 IU of vitamin D.
Adequate calcium and vitamin D supplementation is key to ensure prevention of progressive bone
loss.
Calcium and vitamin D alone are insufficient to prevent fracture in
those with osteoporosis.
ABOUBAKR ELNASHAR
3. Phytoestrogens
Studies do not support the use of soy foods
to prevent osteoporosis.
A well-designed trial in postmenopausal women found that ipriflavone, a synthetic phytoestrogen, did
not decrease bone loss. Furthermore, use was associated with subclinical lymphocytopenia.
ABOUBAKR ELNASHAR
II. Regular exercise
•In children& adolescents:
Wt-bearing physical activity e.g.walking or running contributes to
higher peak bone mass.
•In postmenopausal:
weight-bearing exercise produces small increases in bone
density at the hip and improvement in balance& strength.
Exercise in postmenopausal:
resistance training {improve muscle mass, strength and balance}
balance training which should be performed three times/w
•Women with established osteoporosis:
Activities that place an anterior load on the vertebral bodies e.g.
forward flexion exercises: increased incidence of new vertebral
deformities, and patients should be advised to avoid them.
ABOUBAKR ELNASHAR
III. Avoidance of adverse health habits
1. Current smoking, compared with never smoking,
doubles the risk of hip fracture.
2. Consumption of more than 1 alcoholic drink/day or
more than 7/week is associated with osteoporosis
and fracture, while moderate consumption of 1 drink/day or less is associated with decreased
risk.
3. Excessive caffeine intake is also associated with
increased osteoporosis risk and should be avoided.
ABOUBAKR ELNASHAR
IV. Medication for osteoporosis prevention
•Indications
T-scores below -2 with no other risk factors
T-scores below -1.5 (but not below -2) with one or more major risk factors
A previous fracture of the hip or vertebral bones in the spine
•FDA has approved
1. Bisphosphonates: most commonly prescribed medication for
preventing osteoporosis in those at high risk.
Bisphosphonates are available in daily, weekly, or once-a-month
tablets
2. HRT: Premarin
3. SERM: Evista
Hormone therapy & raloxafene :
a. other menopausal symptoms such as hot flashes
b. side effects e.g. nausea, from oral bisphosphonates.
ABOUBAKR ELNASHAR
V. Avoid certain medications
in those with a high risk of developing osteoporosis
1. Corticosteroids,
2. Heparin
3. Vitamin A
4. Certain antiepileptics: phenytoin [dilantin],
carbamazepine [Tegretol], primidone [Mysoline],
phenobarbital [Nembutal], and valproate [Depakene]
ABOUBAKR ELNASHAR
VI. Fall reduction
•Falls are the direct cause of more than 90% of osteoporotic hip
fractures,and the tendency to fall increases with age.
•Some studies have shown that, for women over age 70, the
most important predictors of hip fractures are fall-related factors
such as poor cognitive function, slow gait and otherwise
impaired mobility, poor vision, drugs that impair alertness or
balance, and history of falls.
In women over 75, age and slow gait are equal to low BMD of
the femoral neck as predictors of hip fracture.Unfortunately,
labeling women as osteopenic or osteoporotic can cause fear of
falling and lack of activity, leading to further acceleration of bone
loss.
ABOUBAKR ELNASHAR
1. Medications that interfere with balance or alertness should be
avoided if possible.
2. Environmental hazards such as loose rugs and uneven or
slippery surfaces are also well-recognized modifiable risks for
fallsthat should be eliminated.
3. Hip protectors effectively reduce fractures in the frail elderly
and can boost confidence for beneficial increases in physical
activity levels, but they are often poorly accepted by patients.
4. Other options include referral for gait training, home visits by a
physician or nurse to identify problems in the home that increase
the risk of falls, or providing information on home modification
(such as installing bathtub rails, removing throw rugs, etc.).
ABOUBAKR ELNASHAR
Role of Gynecologist
ABOUBAKR ELNASHAR
•Women consult the gynecologist
early in their reproductive period,
during pregnancy,
lactation,
premenopausal &
postmenopausal periods for different reasons.
These consultations are precious opportunities for
prevention of osteoporosis.
ABOUBAKR ELNASHAR
•The gynecologist prescribes many drugs & manage
different conditions that might be related to or affect the
risk of osteoporosis.
•The gynecologist should be familiar with:
Risk factors
Early detection & prevention of osteoporosis.
•Prevention efforts should be a routine part of the WHC.
ABOUBAKR ELNASHAR
I- At adolescent & adult age
A. To achieve a peak bone mass in susceptible group.
•Late menarche
•Menstrual interruptions/irregularities
•Pregnancy
•Lactation
B. To reduce bone loss secondary to drugs:
•Gn Rha.
•Dopamine Agonist
•Glucocortocoied
•Depo-provera??
ABOUBAKR ELNASHAR
Adolescent Girls
Disordered eating,amenorrhea, Osteoporosis
Turner Syndrome
90% had osteopenia or osteoporosis
Length of estrogen treatment& BMI showed a positive
association with BMD.
GNRHa for endometriosis:
Add-back’ (oestrogen + progestagen) therapy protects
against BMD loss at the lumbar spine during treatment
and for up to 6 and 12 months after treatment,
respectively (ESHRE Guideline 2005 & RCOG 2006 Grade A)
ABOUBAKR ELNASHAR
II- At peri-menopause
To prevent osteoporosis in high risk group
1-Screening
2-Management
III-At Late post-menopause
To prevent age related osteoporosis (>65y)
Usually it is an orthopedic role
ABOUBAKR ELNASHAR
Conclusion
1. Because of the economic & social burdens,
comprehensive prevention programs are
needed.
2. The role of the gynecologist is important in all
types & different strategies of prevention of
osteoporosis.
ABOUBAKR ELNASHAR
ABOUBAKR ELNASHAR

Más contenido relacionado

La actualidad más candente

Recurrent pregnancy loss 1
Recurrent pregnancy loss 1Recurrent pregnancy loss 1
Recurrent pregnancy loss 1drmcbansal
 
Transverse lie and cord prolapse
Transverse lie and cord prolapseTransverse lie and cord prolapse
Transverse lie and cord prolapsehemnathsubedii
 
13. intrahepatic cholestasis of pregnancy3rd jun 15
13. intrahepatic cholestasis of pregnancy3rd jun 1513. intrahepatic cholestasis of pregnancy3rd jun 15
13. intrahepatic cholestasis of pregnancy3rd jun 15Pawan KB Agrawal
 
Hepatitis and pregnancy warda
Hepatitis and pregnancy wardaHepatitis and pregnancy warda
Hepatitis and pregnancy wardaOsama Warda
 
Recurrent pregnancy loss: case scenario
Recurrent pregnancy loss: case scenarioRecurrent pregnancy loss: case scenario
Recurrent pregnancy loss: case scenarioAboubakr Elnashar
 
Anticoagulation therapy during pregnancy
Anticoagulation therapy during pregnancyAnticoagulation therapy during pregnancy
Anticoagulation therapy during pregnancyRamachandra Barik
 
Multifetal pregnancy (Twins Pregnancy)
Multifetal pregnancy (Twins Pregnancy)Multifetal pregnancy (Twins Pregnancy)
Multifetal pregnancy (Twins Pregnancy)nishma bajracharya
 
Precocious puberty ppt
Precocious puberty pptPrecocious puberty ppt
Precocious puberty pptEmmanuel Umoh
 
Recurrent pregnancy loss
Recurrent pregnancy lossRecurrent pregnancy loss
Recurrent pregnancy lossPriya Bhave.
 
Preventing preterm labour
Preventing preterm labourPreventing preterm labour
Preventing preterm labourlimgengyan
 
PCOD (Polycystic Ovarian Disease)
PCOD (Polycystic Ovarian Disease)PCOD (Polycystic Ovarian Disease)
PCOD (Polycystic Ovarian Disease)Piyush Ranjan Sahoo
 
OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE, Mob: 7289915...
OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE,  Mob: 7289915...OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE,  Mob: 7289915...
OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE, Mob: 7289915...Pradeep Garg
 
Systemic lupus erythematosus During pregnancy
Systemic lupus erythematosus During pregnancySystemic lupus erythematosus During pregnancy
Systemic lupus erythematosus During pregnancyAboubakr Elnashar
 

La actualidad más candente (20)

Choriocarcinoma
Choriocarcinoma Choriocarcinoma
Choriocarcinoma
 
Genital prolapse
Genital prolapseGenital prolapse
Genital prolapse
 
Recurrent pregnancy loss 1
Recurrent pregnancy loss 1Recurrent pregnancy loss 1
Recurrent pregnancy loss 1
 
seminar on neonatal seizure
seminar on neonatal seizureseminar on neonatal seizure
seminar on neonatal seizure
 
Transverse lie and cord prolapse
Transverse lie and cord prolapseTransverse lie and cord prolapse
Transverse lie and cord prolapse
 
Aub ieta -lucknow
Aub   ieta -lucknowAub   ieta -lucknow
Aub ieta -lucknow
 
13. intrahepatic cholestasis of pregnancy3rd jun 15
13. intrahepatic cholestasis of pregnancy3rd jun 1513. intrahepatic cholestasis of pregnancy3rd jun 15
13. intrahepatic cholestasis of pregnancy3rd jun 15
 
Hepatitis and pregnancy warda
Hepatitis and pregnancy wardaHepatitis and pregnancy warda
Hepatitis and pregnancy warda
 
Recurrent pregnancy loss: case scenario
Recurrent pregnancy loss: case scenarioRecurrent pregnancy loss: case scenario
Recurrent pregnancy loss: case scenario
 
Anticoagulation therapy during pregnancy
Anticoagulation therapy during pregnancyAnticoagulation therapy during pregnancy
Anticoagulation therapy during pregnancy
 
Multifetal pregnancy (Twins Pregnancy)
Multifetal pregnancy (Twins Pregnancy)Multifetal pregnancy (Twins Pregnancy)
Multifetal pregnancy (Twins Pregnancy)
 
Precocious puberty ppt
Precocious puberty pptPrecocious puberty ppt
Precocious puberty ppt
 
AMH & its Clinical Implications.pptx
AMH & its Clinical Implications.pptxAMH & its Clinical Implications.pptx
AMH & its Clinical Implications.pptx
 
Recurrent pregnancy loss
Recurrent pregnancy lossRecurrent pregnancy loss
Recurrent pregnancy loss
 
Preventing preterm labour
Preventing preterm labourPreventing preterm labour
Preventing preterm labour
 
tumor markers
tumor markerstumor markers
tumor markers
 
PCOD (Polycystic Ovarian Disease)
PCOD (Polycystic Ovarian Disease)PCOD (Polycystic Ovarian Disease)
PCOD (Polycystic Ovarian Disease)
 
OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE, Mob: 7289915...
OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE,  Mob: 7289915...OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE,  Mob: 7289915...
OPERATIONS FOR NULLIPAROUS PROLAPSE AND VAGINAL VAULT PROLAPSE, Mob: 7289915...
 
Systemic lupus erythematosus During pregnancy
Systemic lupus erythematosus During pregnancySystemic lupus erythematosus During pregnancy
Systemic lupus erythematosus During pregnancy
 
Ovarian hyper stimulation syndrome ohss
Ovarian hyper stimulation syndrome ohssOvarian hyper stimulation syndrome ohss
Ovarian hyper stimulation syndrome ohss
 

Destacado

Progestogens in obstetrics: Which type and route????
Progestogens in obstetrics: Which type and route????Progestogens in obstetrics: Which type and route????
Progestogens in obstetrics: Which type and route????Aboubakr Elnashar
 
PREGNANCY OUTCOMES AFTER ART
PREGNANCY OUTCOMES AFTER ARTPREGNANCY OUTCOMES AFTER ART
PREGNANCY OUTCOMES AFTER ARTAboubakr Elnashar
 
Pelvic Inflammatory Disease CDC, 2010 European Guidelines, 2012
Pelvic Inflammatory Disease CDC, 2010 European Guidelines, 2012Pelvic Inflammatory Disease CDC, 2010 European Guidelines, 2012
Pelvic Inflammatory Disease CDC, 2010 European Guidelines, 2012Aboubakr Elnashar
 
Risks & benefits of combined oral contraceptive pills
Risks & benefits of  combined oral  contraceptive pillsRisks & benefits of  combined oral  contraceptive pills
Risks & benefits of combined oral contraceptive pillsAboubakr Elnashar
 
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
THROMBOPROPHYLAXIS  DURING PREGNANCY, LABOUR  AND AFTER DELIVERYTHROMBOPROPHYLAXIS  DURING PREGNANCY, LABOUR  AND AFTER DELIVERY
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERYAboubakr Elnashar
 
Management of adenxal mass during pregnancy
Management of adenxal mass during pregnancyManagement of adenxal mass during pregnancy
Management of adenxal mass during pregnancyAboubakr Elnashar
 
Uses of aromatase inhibitors in gynecology
Uses of   aromatase inhibitors   in gynecologyUses of   aromatase inhibitors   in gynecology
Uses of aromatase inhibitors in gynecologyAboubakr Elnashar
 
CLINICAL-CYTOGENETIC CORRELATIONS IN UTERINE LEIOMYOMAS
CLINICAL-CYTOGENETIC CORRELATIONS IN UTERINE LEIOMYOMASCLINICAL-CYTOGENETIC CORRELATIONS IN UTERINE LEIOMYOMAS
CLINICAL-CYTOGENETIC CORRELATIONS IN UTERINE LEIOMYOMASAboubakr Elnashar
 
Colposcopy of cevicovaginitis
Colposcopy of  cevicovaginitisColposcopy of  cevicovaginitis
Colposcopy of cevicovaginitisAboubakr Elnashar
 
Initial Evaluation and Referral Guidelines for Management of Pelvic/Ovarian M...
Initial Evaluation and Referral Guidelines for Management of Pelvic/Ovarian M...Initial Evaluation and Referral Guidelines for Management of Pelvic/Ovarian M...
Initial Evaluation and Referral Guidelines for Management of Pelvic/Ovarian M...Aboubakr Elnashar
 
OVARIAN CYSTS IN POSTMENOPAUSAL WOMEN RCOG guidelines, 2003
OVARIAN CYSTS  IN POSTMENOPAUSAL WOMEN  RCOG guidelines, 2003OVARIAN CYSTS  IN POSTMENOPAUSAL WOMEN  RCOG guidelines, 2003
OVARIAN CYSTS IN POSTMENOPAUSAL WOMEN RCOG guidelines, 2003Aboubakr Elnashar
 
Sex education in Egypt: Sources, attitudes and the effect of gender
Sex education in Egypt: Sources, attitudes and the effect of gender Sex education in Egypt: Sources, attitudes and the effect of gender
Sex education in Egypt: Sources, attitudes and the effect of gender Aboubakr Elnashar
 

Destacado (20)

Progestogens in obstetrics: Which type and route????
Progestogens in obstetrics: Which type and route????Progestogens in obstetrics: Which type and route????
Progestogens in obstetrics: Which type and route????
 
PREGNANCY OUTCOMES AFTER ART
PREGNANCY OUTCOMES AFTER ARTPREGNANCY OUTCOMES AFTER ART
PREGNANCY OUTCOMES AFTER ART
 
Pelvic Inflammatory Disease CDC, 2010 European Guidelines, 2012
Pelvic Inflammatory Disease CDC, 2010 European Guidelines, 2012Pelvic Inflammatory Disease CDC, 2010 European Guidelines, 2012
Pelvic Inflammatory Disease CDC, 2010 European Guidelines, 2012
 
Risks & benefits of combined oral contraceptive pills
Risks & benefits of  combined oral  contraceptive pillsRisks & benefits of  combined oral  contraceptive pills
Risks & benefits of combined oral contraceptive pills
 
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
THROMBOPROPHYLAXIS  DURING PREGNANCY, LABOUR  AND AFTER DELIVERYTHROMBOPROPHYLAXIS  DURING PREGNANCY, LABOUR  AND AFTER DELIVERY
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
 
Management of adenxal mass during pregnancy
Management of adenxal mass during pregnancyManagement of adenxal mass during pregnancy
Management of adenxal mass during pregnancy
 
Alternatives to HRT
Alternatives to HRTAlternatives to HRT
Alternatives to HRT
 
Abnormal uterine bleeding
Abnormal  uterine bleedingAbnormal  uterine bleeding
Abnormal uterine bleeding
 
Vaginitis
VaginitisVaginitis
Vaginitis
 
Uses of aromatase inhibitors in gynecology
Uses of   aromatase inhibitors   in gynecologyUses of   aromatase inhibitors   in gynecology
Uses of aromatase inhibitors in gynecology
 
Twin pregnancy protocol
Twin pregnancy protocolTwin pregnancy protocol
Twin pregnancy protocol
 
Operative gynecology
Operative gynecologyOperative gynecology
Operative gynecology
 
METHODS OF CONTRACEPTION
METHODS OF CONTRACEPTION METHODS OF CONTRACEPTION
METHODS OF CONTRACEPTION
 
CLINICAL-CYTOGENETIC CORRELATIONS IN UTERINE LEIOMYOMAS
CLINICAL-CYTOGENETIC CORRELATIONS IN UTERINE LEIOMYOMASCLINICAL-CYTOGENETIC CORRELATIONS IN UTERINE LEIOMYOMAS
CLINICAL-CYTOGENETIC CORRELATIONS IN UTERINE LEIOMYOMAS
 
Colposcopy of cevicovaginitis
Colposcopy of  cevicovaginitisColposcopy of  cevicovaginitis
Colposcopy of cevicovaginitis
 
Initial Evaluation and Referral Guidelines for Management of Pelvic/Ovarian M...
Initial Evaluation and Referral Guidelines for Management of Pelvic/Ovarian M...Initial Evaluation and Referral Guidelines for Management of Pelvic/Ovarian M...
Initial Evaluation and Referral Guidelines for Management of Pelvic/Ovarian M...
 
OVARIAN CYSTS IN POSTMENOPAUSAL WOMEN RCOG guidelines, 2003
OVARIAN CYSTS  IN POSTMENOPAUSAL WOMEN  RCOG guidelines, 2003OVARIAN CYSTS  IN POSTMENOPAUSAL WOMEN  RCOG guidelines, 2003
OVARIAN CYSTS IN POSTMENOPAUSAL WOMEN RCOG guidelines, 2003
 
Sex education in Egypt: Sources, attitudes and the effect of gender
Sex education in Egypt: Sources, attitudes and the effect of gender Sex education in Egypt: Sources, attitudes and the effect of gender
Sex education in Egypt: Sources, attitudes and the effect of gender
 
PELVIC INFLAMMATORY DISEASE
PELVIC INFLAMMATORY DISEASEPELVIC INFLAMMATORY DISEASE
PELVIC INFLAMMATORY DISEASE
 
Osteoporosis
OsteoporosisOsteoporosis
Osteoporosis
 

Similar a The role of the gynecologist in screening & prevention of Osteoporosis

Similar a The role of the gynecologist in screening & prevention of Osteoporosis (20)

Postmenopausal Osteoporosis
Postmenopausal OsteoporosisPostmenopausal Osteoporosis
Postmenopausal Osteoporosis
 
Osteoporosis : nightmare of menopause
Osteoporosis : nightmare of menopauseOsteoporosis : nightmare of menopause
Osteoporosis : nightmare of menopause
 
Management of osteoporosis
Management of osteoporosisManagement of osteoporosis
Management of osteoporosis
 
Osteoprosis
OsteoprosisOsteoprosis
Osteoprosis
 
METABOLIC BONE DISEASE MANASIL.pptx
 METABOLIC BONE DISEASE MANASIL.pptx METABOLIC BONE DISEASE MANASIL.pptx
METABOLIC BONE DISEASE MANASIL.pptx
 
2017 upto date osteoprosis
2017 upto date osteoprosis2017 upto date osteoprosis
2017 upto date osteoprosis
 
Osteoporosis in elderly causes and management
Osteoporosis in elderly causes and managementOsteoporosis in elderly causes and management
Osteoporosis in elderly causes and management
 
Osteoporosis
OsteoporosisOsteoporosis
Osteoporosis
 
FA Presentation 12 Mimi Fan
FA Presentation 12 Mimi FanFA Presentation 12 Mimi Fan
FA Presentation 12 Mimi Fan
 
Managment of glucocorticoids induced osteoprosis
Managment of glucocorticoids induced osteoprosisManagment of glucocorticoids induced osteoprosis
Managment of glucocorticoids induced osteoprosis
 
Osteoporosis UnAd
Osteoporosis UnAdOsteoporosis UnAd
Osteoporosis UnAd
 
OSTEOPOROSIS: A Barebone guide to diagnosis and management
OSTEOPOROSIS:A Barebone guide to diagnosis and managementOSTEOPOROSIS:A Barebone guide to diagnosis and management
OSTEOPOROSIS: A Barebone guide to diagnosis and management
 
Osteoporosis - Dr S L Yadav
Osteoporosis - Dr S L YadavOsteoporosis - Dr S L Yadav
Osteoporosis - Dr S L Yadav
 
Osteoporosis
OsteoporosisOsteoporosis
Osteoporosis
 
Osteoporosis_Women's_Health_6.ppt
Osteoporosis_Women's_Health_6.pptOsteoporosis_Women's_Health_6.ppt
Osteoporosis_Women's_Health_6.ppt
 
Osteoporosis
OsteoporosisOsteoporosis
Osteoporosis
 
Osteoporosis
OsteoporosisOsteoporosis
Osteoporosis
 
Osteoporosis
OsteoporosisOsteoporosis
Osteoporosis
 
Osteoporosis a
Osteoporosis aOsteoporosis a
Osteoporosis a
 
Osteoporosis
OsteoporosisOsteoporosis
Osteoporosis
 

Más de Aboubakr Elnashar

WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTWHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTAboubakr Elnashar
 
Adenomyosis associated infertility
Adenomyosis associated  infertilityAdenomyosis associated  infertility
Adenomyosis associated infertilityAboubakr Elnashar
 
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Aboubakr Elnashar
 
Aesthetic gynecology controversy
Aesthetic gynecology controversyAesthetic gynecology controversy
Aesthetic gynecology controversyAboubakr Elnashar
 
Hormonal assay in clinical gyn
Hormonal assay in clinical gynHormonal assay in clinical gyn
Hormonal assay in clinical gynAboubakr Elnashar
 
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineUnnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineAboubakr Elnashar
 
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationIndividualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationAboubakr Elnashar
 
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA Aboubakr Elnashar
 
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021  cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021 Aboubakr Elnashar
 
Management of pregnancy of unknown location
Management of pregnancy of unknown locationManagement of pregnancy of unknown location
Management of pregnancy of unknown locationAboubakr Elnashar
 
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021Aboubakr Elnashar
 

Más de Aboubakr Elnashar (20)

WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTWHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
 
hepatitis B.pdf
hepatitis B.pdfhepatitis B.pdf
hepatitis B.pdf
 
hepatitis c2022.pdf
hepatitis c2022.pdfhepatitis c2022.pdf
hepatitis c2022.pdf
 
Adenomyosis associated infertility
Adenomyosis associated  infertilityAdenomyosis associated  infertility
Adenomyosis associated infertility
 
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022
 
Adenxal mass guidelines2020
Adenxal mass guidelines2020Adenxal mass guidelines2020
Adenxal mass guidelines2020
 
Aesthetic gynecology controversy
Aesthetic gynecology controversyAesthetic gynecology controversy
Aesthetic gynecology controversy
 
Hormonal assay in clinical gyn
Hormonal assay in clinical gynHormonal assay in clinical gyn
Hormonal assay in clinical gyn
 
FIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVFFIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVF
 
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineUnnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicine
 
Infertility prevention
Infertility prevention Infertility prevention
Infertility prevention
 
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationIndividualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulation
 
Female infertility
Female infertility Female infertility
Female infertility
 
Maternal near miss
Maternal near missMaternal near miss
Maternal near miss
 
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
 
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021  cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021
 
CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT  CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT
 
Management of pregnancy of unknown location
Management of pregnancy of unknown locationManagement of pregnancy of unknown location
Management of pregnancy of unknown location
 
Aerobic Vaginitis
Aerobic Vaginitis Aerobic Vaginitis
Aerobic Vaginitis
 
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021
 

Último

Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxbkling
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptMumux Mirani
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...saminamagar
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
POST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxPOST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxvirengeeta
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 

Último (20)

Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptx
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.ppt
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
POST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxPOST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptx
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 

The role of the gynecologist in screening & prevention of Osteoporosis

  • 1. The role of the gynecologist in screening & prevention of Osteoporosis Aboubakr Elnashar Benha University Hospital ABOUBAKR ELNASHAR
  • 4. Women health Clinic •Screening for breast cancer •Screening for cervical cancer •Pre conceptional counseling •Contraception •Sexual dysfunction •Menopausal •Screening & prevention of osteoporosisABOUBAKR ELNASHAR
  • 5. •Consequences of Hip Fractures 5–20%: mortality within 1 y 20%: severely impaired mobility 50%: do not regain previous mobility • In women >50y, the lifetime risk of (NICE,2008) Vertebral fracture is 1/3 Hip fracture is 1/5 ABOUBAKR ELNASHAR
  • 6. Osteoporosis Silent disease {by the time any symptoms (pain & fractures) became apparent, the disease is already far advanced}. The nightmares of post-menopause Progressive, systemic disorder characterized by: •Low bone mass •Micro-architectural deterioration of bone tissue •Increase in bone fragility & susceptibility to fracture (NICE, 2008) ABOUBAKR ELNASHAR
  • 8. Sites: Any Common •Lumbar & thoracic spine •Proximal femur. •Distal radius ABOUBAKR ELNASHAR
  • 9. Bone mass •35% of cortical & 50% of cancellous bone mass are lost over a lifetime •The peak bone mass attained is a major determinant of subsequent bone mass& fracture risk in later life (Bonjour et al,1997). ABOUBAKR ELNASHAR
  • 10. •Determinants of peak bone mass Genetic factors: At least half of bone strength is attributable to genetic factors; Genetic risk factors: age, family history, female sex, low wt, small frame, and white or Asian race. Gonadal status Nutritional status Physical activity Modifiable factors may contribute almost equally ABOUBAKR ELNASHAR
  • 12. The US Preventive Services Task Force American Association of Clinical Endocrinologists, The North American Menopause Society, The American College of Obstetricians and Gynecologists, •Indications ABOUBAKR ELNASHAR
  • 16. Major • Age ≥ 65 yr • Vertebral compression fracture • Fragility fracture after age 40 yr • Family history of osteoporotic fracture • Systemic glucocorticoid therapy ≥ 3 mo • Malabsorption syndrome • Primary hyperparathyroidism • Propensity to fall • Appearance of osteopenia on radiograph • Hypogonadism •Early menopause (< 45 yr) Minor • Rheumatoid arthritis • History of clinical hyperthyroidism • Long-term anticonvulsant therapy • Weight loss > 10% of body wt at age 25 y • Weight < 57 kg • Smoking • Excess alcohol intake • Excess caffeine intake • Low dietary calcium intake • Long-term heparin therapy V. 1 major or 2 minor clinical factors (SOGC Clinical Practice Guideline, 2009) ABOUBAKR ELNASHAR
  • 17. The FRAX® tool has been developed by WHO to evaluate fracture risk of patients. It is based on individual patient models that integrate the risks associated with clinical risk factors as well as bone mineral density (BMD) at the femoral neck. The FRAX® models have been developed from studying population-based cohorts from Europe, North America, Asia and Australia. In their most sophisticated form, the FRAX® tool is computer-driven and is available on this site. Several simplified paper versions, based on the number of risk factors are also available, and can be downloaded for office use. The FRAX® algorithms give the 10-year probability of fracture. The output is a 10-year probability of hip fracture and the 10-year probability of a major osteoporotic fracture (clinical spine, forearm, hip or shoulder fracture). ABOUBAKR ELNASHAR
  • 18. Age Sex Weight Height Previous fracture Parent fractured hip Current smoking Glucocorticoids Rheumatoid arthritis Secondary osteoporosis Alcohol 3 or more units/day Bone mineral density (BMD) ABOUBAKR ELNASHAR
  • 19. Methods I. DEXA (Dual Energy X ray Absorbometry) The best predictor of hip fracture and an equivalent predictor of other fractures. The total hip, femoral neck, and posterior-anterior lumbar spine should be measured, using the lowest of the three BMD scores. The technical standard (ACOG, 2004) •Measures important sites of osteoporotic fractures. •High precision& accuracy. •Relatively inexpensive •Modest radiation exposure . ABOUBAKR ELNASHAR
  • 20. DEXA: 2 x-ray beams of different energy levels ABOUBAKR ELNASHAR
  • 22. Interpreting DEXA Results T scores (comparison with the young adult mean): relates to absolute fracture risk Z scores (comparison with reference values of the same age): related to the individual’s relative risk for their age. ABOUBAKR ELNASHAR
  • 23. •T score ≥ -1 •T score -1 to -2.5 •T score < -2.5 Normal Osteopenia Osteoporosis WHO Classification of BMD using DEXA •T score < -2.5 + H. of fractureSevere Osteoporosis T score represents the number of SD a patient is above or below the mean BMD of a young adult. ABOUBAKR ELNASHAR
  • 24. Australian Family Physician, 2004 ABOUBAKR ELNASHAR
  • 25. II. Tests other than DEXA (peripheral bone densitometry devices (ACOG guideline, 2004) 1. Quantitative US (QUS) . 2. Single-energy x-ray absorptiometry. 3. Peripheral DEXA 4. Peripheral quantitative computed tomography less expensive low radiation exposure low precision& accuracy. Measure peripheral bone only. Cannot replace DEXA scans . ABOUBAKR ELNASHAR
  • 27. III. Biochemical markers. Reflect bone turnover Have potential use in diagnosing& monitoring therapy of osteoporosis. Not recommended at this time. ABOUBAKR ELNASHAR
  • 29. • Types of prevention of osteoporosis. 1. Primary: Aims at reaching at adolescent age a peak bone mass as high as possible. Should begin in childhood& continue throughout the life span to maximize bone mass. E.g. sufficient calcium intake, omit risk factors 2. Secondary: Aims at reducing bone loss peri & postmenopausal E.g. estrogens/gestagens, bisphosphonates &SERMs. 3. Tertiary: With manifest osteoporosis aims at preventing fractures. ABOUBAKR ELNASHAR
  • 30. Strategies for prevention of osteoporosis: 1. High risk strategy: To identify women at risk & offer intervention 2. Global strategy: Population based, where the aim is to modify the risk factors in the general community ABOUBAKR ELNASHAR
  • 31. 5 steps for maximizing peak bone mass (National osteoporosis foundation) Most important for women who haven't reached their maximum peak bone mass, which usually occurs around the age of 30. Step 1: Daily recommended amounts of ca & vitamin D Step 2: Regular wt-bearing exercises Step 3: Avoid smoking& excessive alcohol intake Step 4: Risk factor assessment of developing osteoporosis. To institute strategies to maximize peak bone mass and minimize loss before it is too late to prevent the disease. Step 5: When indicated, BMD test to see if medication is needed ABOUBAKR ELNASHAR
  • 32. 5 steps to minimizing bone loss especially after menopause (National osteoporosis foundation) Step 1: Balanced diet Regular exercise program Adequate intake of calcium in diet, Regular sunlight exposure Step 2: Stop smoking and reduce alcohol consumption Step 3: Risk factor assessment & screening test Step 4: If required, medication for osteoporosis prevention Step 5: Avoid certain medications ABOUBAKR ELNASHAR
  • 34. I. Improvement of nutritional intake 1. Ca Adequate consumption of calcium is essential for bone health. Calcium balance also can be adversely affected by dietary habits, including high intake of protein, phosphorus, and sodium, although these effects appear to be less important when dietary calcium is sufficient. The recommended calcium intake for postmenopausal women (1200–1500 mg/day) can be met with food sources, but supplements should be added if needed. Most postmenopausal women in the USA consume only about 600 mg/d. High-calcium foods include milk (290–300 mg/cup), sardines in oil, with bones (370 mg/3 oz), yogurt (300–500 mg depending on container size), cheese (165–270 mg/slice), canned salmon, with bones (170–210 mg/3 oz), broccoli (160–180 mg/cup), and tofu (144–155 mg/4 oz). ABOUBAKR ELNASHAR
  • 35. 2. Vitamin D Essential for intestinal absorption of calcium. The recommended intake for women is 400 IU/d for ages 51 to 70, 600 IU/d over age 70, and 800 IU/day for all high-risk women (homebound, institutionalized, on chronic glucocorticoids, or who live in northern latitudes and therefore have limited exposure to sunlight) Sources of vitamin D include sunlight, vitamin D–fortified foods, fish oils, and supplements. Multivitamins typically contain 400 IU of vitamin D. Adequate calcium and vitamin D supplementation is key to ensure prevention of progressive bone loss. Calcium and vitamin D alone are insufficient to prevent fracture in those with osteoporosis. ABOUBAKR ELNASHAR
  • 36. 3. Phytoestrogens Studies do not support the use of soy foods to prevent osteoporosis. A well-designed trial in postmenopausal women found that ipriflavone, a synthetic phytoestrogen, did not decrease bone loss. Furthermore, use was associated with subclinical lymphocytopenia. ABOUBAKR ELNASHAR
  • 37. II. Regular exercise •In children& adolescents: Wt-bearing physical activity e.g.walking or running contributes to higher peak bone mass. •In postmenopausal: weight-bearing exercise produces small increases in bone density at the hip and improvement in balance& strength. Exercise in postmenopausal: resistance training {improve muscle mass, strength and balance} balance training which should be performed three times/w •Women with established osteoporosis: Activities that place an anterior load on the vertebral bodies e.g. forward flexion exercises: increased incidence of new vertebral deformities, and patients should be advised to avoid them. ABOUBAKR ELNASHAR
  • 38. III. Avoidance of adverse health habits 1. Current smoking, compared with never smoking, doubles the risk of hip fracture. 2. Consumption of more than 1 alcoholic drink/day or more than 7/week is associated with osteoporosis and fracture, while moderate consumption of 1 drink/day or less is associated with decreased risk. 3. Excessive caffeine intake is also associated with increased osteoporosis risk and should be avoided. ABOUBAKR ELNASHAR
  • 39. IV. Medication for osteoporosis prevention •Indications T-scores below -2 with no other risk factors T-scores below -1.5 (but not below -2) with one or more major risk factors A previous fracture of the hip or vertebral bones in the spine •FDA has approved 1. Bisphosphonates: most commonly prescribed medication for preventing osteoporosis in those at high risk. Bisphosphonates are available in daily, weekly, or once-a-month tablets 2. HRT: Premarin 3. SERM: Evista Hormone therapy & raloxafene : a. other menopausal symptoms such as hot flashes b. side effects e.g. nausea, from oral bisphosphonates. ABOUBAKR ELNASHAR
  • 40. V. Avoid certain medications in those with a high risk of developing osteoporosis 1. Corticosteroids, 2. Heparin 3. Vitamin A 4. Certain antiepileptics: phenytoin [dilantin], carbamazepine [Tegretol], primidone [Mysoline], phenobarbital [Nembutal], and valproate [Depakene] ABOUBAKR ELNASHAR
  • 41. VI. Fall reduction •Falls are the direct cause of more than 90% of osteoporotic hip fractures,and the tendency to fall increases with age. •Some studies have shown that, for women over age 70, the most important predictors of hip fractures are fall-related factors such as poor cognitive function, slow gait and otherwise impaired mobility, poor vision, drugs that impair alertness or balance, and history of falls. In women over 75, age and slow gait are equal to low BMD of the femoral neck as predictors of hip fracture.Unfortunately, labeling women as osteopenic or osteoporotic can cause fear of falling and lack of activity, leading to further acceleration of bone loss. ABOUBAKR ELNASHAR
  • 42. 1. Medications that interfere with balance or alertness should be avoided if possible. 2. Environmental hazards such as loose rugs and uneven or slippery surfaces are also well-recognized modifiable risks for fallsthat should be eliminated. 3. Hip protectors effectively reduce fractures in the frail elderly and can boost confidence for beneficial increases in physical activity levels, but they are often poorly accepted by patients. 4. Other options include referral for gait training, home visits by a physician or nurse to identify problems in the home that increase the risk of falls, or providing information on home modification (such as installing bathtub rails, removing throw rugs, etc.). ABOUBAKR ELNASHAR
  • 44. •Women consult the gynecologist early in their reproductive period, during pregnancy, lactation, premenopausal & postmenopausal periods for different reasons. These consultations are precious opportunities for prevention of osteoporosis. ABOUBAKR ELNASHAR
  • 45. •The gynecologist prescribes many drugs & manage different conditions that might be related to or affect the risk of osteoporosis. •The gynecologist should be familiar with: Risk factors Early detection & prevention of osteoporosis. •Prevention efforts should be a routine part of the WHC. ABOUBAKR ELNASHAR
  • 46. I- At adolescent & adult age A. To achieve a peak bone mass in susceptible group. •Late menarche •Menstrual interruptions/irregularities •Pregnancy •Lactation B. To reduce bone loss secondary to drugs: •Gn Rha. •Dopamine Agonist •Glucocortocoied •Depo-provera?? ABOUBAKR ELNASHAR
  • 47. Adolescent Girls Disordered eating,amenorrhea, Osteoporosis Turner Syndrome 90% had osteopenia or osteoporosis Length of estrogen treatment& BMI showed a positive association with BMD. GNRHa for endometriosis: Add-back’ (oestrogen + progestagen) therapy protects against BMD loss at the lumbar spine during treatment and for up to 6 and 12 months after treatment, respectively (ESHRE Guideline 2005 & RCOG 2006 Grade A) ABOUBAKR ELNASHAR
  • 48. II- At peri-menopause To prevent osteoporosis in high risk group 1-Screening 2-Management III-At Late post-menopause To prevent age related osteoporosis (>65y) Usually it is an orthopedic role ABOUBAKR ELNASHAR
  • 49. Conclusion 1. Because of the economic & social burdens, comprehensive prevention programs are needed. 2. The role of the gynecologist is important in all types & different strategies of prevention of osteoporosis. ABOUBAKR ELNASHAR